RXi Pharmaceuticals Corporation (RXII) to Release Quarterly Earnings on Wednesday
RXi Pharmaceuticals Corporation (NASDAQ:RXII) is scheduled to announce its earnings results after the market closes on Wednesday, November 8th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter.
RXi Pharmaceuticals Corporation (NASDAQ:RXII) last posted its earnings results on Thursday, August 10th. The biotechnology company reported ($0.11) EPS for the quarter, hitting the consensus estimate of ($0.11). During the same quarter in the prior year, the firm posted ($0.34) earnings per share. On average, analysts expect RXi Pharmaceuticals Corporation to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
RXi Pharmaceuticals Corporation (RXII) opened at $0.57 on Monday.
In other RXi Pharmaceuticals Corporation news, insider Alexey Eliseev sold 176,800 shares of the company’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $0.54, for a total value of $95,472.00. Following the completion of the transaction, the insider now owns 1,100,931 shares in the company, valued at approximately $594,502.74. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 5.71% of the stock is currently owned by corporate insiders.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.
Receive News & Ratings for RXi Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.